众生药业：预计2025年度净利润为2.6亿元~3.1亿元

Company Performance - The company expects a net profit attributable to shareholders of 260 million to 310 million yuan for 2025, marking a turnaround from a loss in the previous year [1] - Basic earnings per share are projected to be between 0.31 yuan and 0.37 yuan, compared to a loss of 0.36 yuan per share in the same period last year [1] Strategic Focus - The performance change is primarily attributed to the company's strategic positioning of "traditional Chinese medicine as the foundation, innovation leading, and quality and efficiency being prioritized" [1] - The company is concentrating resources on the research and development of innovative drugs in the treatment areas of metabolic diseases and respiratory diseases [1] Growth Drivers - Two innovative drugs, Lai Ruitewei tablets and Angladiwei tablets, have been approved for market launch, which are expected to be significant growth drivers for the company's future performance [1]